

2019 #2

January 25, 2019

INSIDE:

Status and Impact of
Shutdown on
FDA/CBER/OBRR2

CHILL Study Published ...3

Results from 2018 Industry
Employee Turnover and
Retention Survey3

57th ABC Annual Meeting
Registration Open3

Upcoming ABC Webinars
– Don't Miss Out!3

RESEARCH IN BRIEF4

PEOPLE6

MEMBER NEWS6

INFECTIOUS DISEASE
UPDATES7

STOPLIGHT®: Status of
America's Blood
Centers' Blood Supply .8

ABC 2019 Meetings &
Workshops9

CALENDAR9

POSITIONS10

ABC CMO to Retire in April



Louis Katz, MD has announced that he will retire as chief medical officer of America's Blood Centers (ABC) in April 2019. "We greatly appreciate Dr. Katz's exemplary leadership on behalf of the industry since joining ABC in 2012," said ABC CEO Kate Fry, MBA in a memo to the ABC membership. "His contributions and accomplishments are lengthy and his commitment unparalleled. While we will miss his wit and candor, we wish him the very best in this next stage and look forward to continuing to benefit from his involvement as a volunteer."

Prior to joining ABC, Dr. Katz served as the executive vice president of Medical Affairs at Mississippi Valley Regional Blood Center (Davenport, Iowa). He is a clinical infectious diseases physician who has overseen a Ryan White Title 3 comprehensive AIDS clinic, served as hospital epidemiologist for Genesis Medical Center in Davenport, and medical director of the Scott County (Iowa) Health Department. He received his medical degree from the University of Iowa College of Medicine, where he trained in internal medicine and infectious diseases, and he is board certified in both. Dr. Katz has served as the chair of ABC's Scientific, Medical, and Technical Committee; as a member and chair of the AABB Transfusion Transmitted Diseases Committee; and as a member and chair of the FDA Blood Products Advisory Committee.

A search committee of ABC member volunteers will assist in identifying an ideal candidate. Additional details including the members of the search committee are available in [MCN 19-006](#). A job listing for the role can be found in the "Positions" section (page 10) of the *ABC Newsletter*.

Please send any inquiries and questions to [Kate Fry](#).

(Source: [MCN 19-006](#), 1/25/19) ♦

We Welcome Your Letters

The *ABC Newsletter* welcomes letters from its readers on any blood-related topic that might be of interest to ABC members. Letters should be kept relatively short and to the point, preferably about a topic that has recently been covered in the *ABC Newsletter*. Letters are subject to editing for brevity and good taste and published after editorial review. Please send letters to the Editor at newsletter@americasblood.org or fax them to (202) 899-2621. Please include your correct title and




Status and Impact of Shutdown on FDA/CBER/OBRR

This statement was received by ABC staff from the Office of Blood Research and Review (OBRR) within the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) on January 23rd:

“Due to the absence of either an FY 2019 appropriation or Continuing Resolution for FDA, we have been and continue to be unable to receive original applications or supplements for the manufacture of blood, blood components and Source Plasma since December 22, 2018. Please note that the review clock for existing submissions of blood, blood, components and Source Plasma received prior to December 22, 2018 has stopped, and will resume when the government reopens.”

ABC is interested in [hearing](#) how the government shutdown impacted member blood centers. This could include loss of drives, delays in FDA approvals, impaired communication from federal agency staff, etc. One member has reported losing nearly 600 units from cancelled drives with government entities. As of publication, media outlets are reporting that President Trump has agreed to a temporary funding measure that reopens the federal government until February 15th ending the 35-day shutdown. 💧



The *ABC Newsletter* (ISSN #1092-0412) is published by America's Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2019 by America's Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher. (ABC members need not obtain prior permission if proper credit is given.)

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognize the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the healthcare system; promote partnerships, policies and programs that increase awareness about the need for blood donation; and serve as a thought-leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

America's Blood Centers

Chief Executive Officer: Kate Fry

Chief Medical Officer: Louis Katz

Editor: Mack Benton

Subscriptions Manager: Leslie Maundy

Annual Subscription Rate: \$390

Send subscription queries to

lmaundy@americasblood.org

America's Blood Centers

1717 K St. NW, Suite 900, Washington, DC 20006

Phone: (202) 393-5725

Send news tips to newsletter@americasblood.org.



America's Blood Centers®
It's About *Life*.

INSIDE ABC

The programs and services described in the Inside ABC section are available to ABC member blood centers and their staff only, unless otherwise specified.

CHILL Study Published

The Comparison of the History of Donation and Iron Levels in Teen Blood Donors (CHILL) study has been published in [Transfusion](#). ABC advocated for data, flexibility, and time in advance of publication of the study and previously distributed resources to member blood centers ([MCN 18-032](#), [public statement](#) and [talking points](#)). We understand that dissenting views exist around the clinical effects of donor iron depletion. ABC remains committed to representing the collective interests of the membership to external stakeholders and encourages member blood centers to prepare to address potential media, education administration, blood donor, and parental questions that may arise from the publication of this study. We welcome [comments and questions](#), and are available to assist in any way.

(Source: [MCN 19-004](#))

Results from 2018 Industry Employee Turnover and Retention Survey

ABC's Human Resources Committee recently announced the availability of the results from the annual Industry Employee Turnover and Retention Survey for calendar year 2017. It is an analysis from 2013–17 reported in aggregate and made available on ABC's member website. The calendar year 2017 report is available [here](#). This industry benchmark report can be used by members to easily identify strengths and opportunities in their own organizations when compared to the industry.

(Source: [MCN 18-056](#))

57th ABC Annual Meeting Registration Open

[Registration](#) is open for America's Blood Centers' (ABC) 57th Annual Meeting in Washington, D.C. March 23rd – 26th, 2019 at the Ritz-Carlton (Pentagon City). Don't miss an exclusive opportunity for blood center leaders to experience peer-to-peer collaboration, while discussing the latest trends impacting community blood centers. The meeting will feature the Celso Bianco, MD Lectureship & Reception, the Scientific, Medical, and Technical Forum, Capitol Hill Visits, General Session, and the 22nd Annual *Awards of Excellence*. Please make your hotel [reservations](#) by March 1st to ensure best availability and the group rate. Click [here](#) for additional details. Contact [Leslie Maundy](#) for available [sponsorship](#) opportunities. ♦

Upcoming ABC Webinars – Don't Miss Out!

- **SMT Journal Club** – April 3rd. Additional details forthcoming!
- **QA Education Webinar – PRT & Double Red Cell Licensure** – April 9th. Additional details forthcoming!
- **QA Education Webinar – Change Management** – July 16th. Additional details forthcoming!



RESEARCH IN BRIEF

The impact of ABO on platelet function. The authors of this *in vitro* study appearing in *Blood* demonstrate that Group O platelets bind to von Willebrand Factor (vWF) less robustly than non-Group O platelets. They suggest this may be “a potential mechanism for the reduced risk of myocardial infarction associated with [individuals who are] blood type O.” Custom-designed parallel plate flow chambers (analogous to artificial blood vessels) coated with vWF and then pressurized to simulate shear forces similar to those seen in human arteries were used. Through these the authors channeled platelets from healthy group O (n = 33) and non-group O (n = 54) blood donors and measured, using video microscopy, platelet-vWF interactions. Group O platelets and Group A platelets were perfused, in crossover fashion, across purified Group O and Group A vWF, respectively. Group O platelets traveled “further [and] at greater speeds before forming stable bonds with vWF.” While the flow characteristics for the group A platelets were similar irrespective of the ABO type of the donors from which the vWF was derived, the group O platelets “translocated for greater distances at higher velocity prior to arresting stably on the surface of vWF O than they did on vWF A.” Subsequent modeling analyses revealed that “the kinetics for [the] GPIIb/IIIa/vWF binding rate are significantly lower for type O compared to non-O platelets.” The authors closed by noting how this “may explain why subjects with blood group O have a reduced risk of myocardial infarction in that O type platelets are less ‘sticky’ on vWF.”

Citations: Dunne, E., Qi, Q.M., Shaqfeh, E.S., *et al.* Blood group alters platelet binding kinetics to von Willebrand Factor and consequently platelet function. *Blood*. 2019. doi: [10.1182/blood-2018-06-855528](https://doi.org/10.1182/blood-2018-06-855528).

Japan approves stem cell treatment for spinal cord injury. Is this too soon? The Japanese Health Ministry has approved the commercialization of an intravenous autologous mesenchymal stem cell therapy to treat patients with traumatic spinal cord injuries, contingent on collecting data during seven years of follow-up. The clearance was based on an unpublished clinical trial in 13 patients under a fast-track regulatory scheme for promising therapies. Twelve of 13 patients are reported to have improved. Independent observers are critical of the approval based on the lack of appropriate blinding, and absence of a consistent mechanistic hypothesis for the effect, and ask if the improvements observed might reflect just the natural history of the injuries.

Citation: Cyranoski, D. Japan’s approval of stem-cell treatment for spinal cord injury concerns scientists. *Nature*. 2019. doi: [10.1038/d41586-019-00178-x](https://doi.org/10.1038/d41586-019-00178-x).

Impact of prior dengue on the risk for Zika infection. Immunity to one of the four dengue types can have significant impacts after subsequent exposure to other types. Zika is a closely related flavivirus that has caused explosive outbreaks in areas with endemic and epidemic dengue. Scientists in the U.S. and Nicaragua have studied the impact of previous dengue infection on the clinical course of Zika in children. They found that the rate of Zika infection is not affected, but that when it occurs it is less severe than in children with no prior dengue. Further research will be needed to confirm and expand these findings, understand the mechanism(s) and time course if cross protection is confirmed, and to study whether preexisting dengue immunity also modifies severe Zika outcomes like neurodevelopmental injury after in utero infection.


Citation: Gordon, A., Gresh, L., Ojeda, S. *et al.* [Prior dengue virus infection and risk of Zika: A pediatric cohort in Nicaragua](https://doi.org/10.1371/journal.pmed.1003111). *PLoS Medicine*. 2019.

Antibodies may be effective to prevent cytomegalovirus (CMV) reactivation, but they have to be the right ones. More than 60 percent of potential blood donors are latently infected with CMV and are at risk to transmit the virus to recipients. CMV disease continues to cause frequent serious morbidity and mortality after stem cell and organ transplantation and continues to stress blood centers that are asked to find that

(continued on page 5)

RESEARCH IN BRIEF (continued from page 4)

minority of blood donors who have never been infected. Screening and administration of preemptive antiviral drugs is the widely used strategy, but it is relatively expensive, resistance to drugs can emerge, and the medications have significant adverse effects. Immunoglobulin infusions using both standard intravenous immunoglobulins and preparations from donors with high titer anti-CMV antibodies have given suboptimal clinical results after stem cell transplantation. A study in *Science* offers another potential therapeutic approach with the observation that effective antibodies must be specific for the infecting CMV strain. In the mouse marrow transplant model used in the paper, serotherapy offered complete protection from reactivation and disease when the antibodies were matched. If translatable, the findings may be important for CMV vaccine development as well, which has languished after disappointing animal and clinical studies.

Citation: Martins, J.P., Andoniou, C.E., Fleming, P. *et al.* Strain-specific antibody therapy prevents cytomegalovirus reactivation after transplantation. *Science*. 2019. doi: [10.1126/science.aat0066](https://doi.org/10.1126/science.aat0066). 

Correction: In ABC Newsletter Issue #1, 2019, we referred to the National Blood Testing Cooperative as the National Blood Testing Collaborative. We apologize for any confusion caused by this error and thank our readers for their ongoing support.

AMERICA'S BLOOD CENTERS'

57TH

ANNUAL MEETING

March 23-26, 2019 | Washington, DC



2019 ANNUAL MEETING SCHEDULE

- Saturday, March 23:** International Blood Safety Forum
ABC Board Meeting
- Sunday, March 24:** General Session
SMT Forum & Celso Bianco Lectureship
Celso Bianco Celebration of Life Reception
- Monday, March 25:** ABC Members Meeting
General Session
22nd Annual Awards of Excellence
- Tuesday, March 26:** Advocacy Forum
Capitol Hill Visits

“ The ABC Annual Meeting is the premiere opportunity for individuals to explore trends amongst peers within the blood community, contribute their thoughts and ideas to important policy discussions with regulators, while sharing their stories with legislators and networking with industry partners. Value exists for professionals of all experience levels. Join us in Washington, D.C.!**”**

—Kate Fry, Chief Executive Officer
America's Blood Centers



America's Blood Centers®
It's About *Life*.




Hotel Information
Ritz-Carlton (Pentagon City)
Hotel room rate: \$259

For registration information, visit http://bit.ly/abc_am19.

For sponsorship opportunities, please contact Leslie Maundy at lmaundy@americasblood.org.



PEOPLE

Amy Efantis became president and CEO of the Plasma Protein Therapeutics Association (PPTA) on January 16th according to an announcement from the PPTA Board of Directors. “We are very pleased that Amy has agreed to take on the leadership for the PPTA at a time of unprecedented change in health care,” said PPTA Global Board Chair David Bell in a news [release](#). “Continued progress in the development of vital and life-saving treatments through the development of plasma protein therapies is critically dependent on the support needed from global stakeholders around the world. Amy has been selected by our Board as we all believe she has the leadership and vision to set the course for PPTA’s future.” Ms. Efantis most recently served as the vice president of Global Public Policy and Government at Biogen in addition to holding previous positions at Boehringer Ingelheim and PhRMA. “I am thrilled and honored to be joining the PPTA and the vital efforts of the plasma industry,” said Ms. Efantis in the news release. “[T]o represent companies whose mission is serving patients with rare diseases that can be treated through the development of plasma-derived products is a stewardship role that I embrace with humility and a deeply felt passion.”

(Source: PPTA News [Release](#), 1/14/18)



Robert Visscher has been named executive director of Global Healing following the retirement of John Donnelly. In addition to his leadership skills, Mr. Visscher has more than 17 years of experience as a communicator, strategic planner, project manager, community advocate/organizer, and public speaker. He previously served in the United States Navy and holds a bachelor’s degree in business and distributive education from Buffalo State University and a master’s degree in divinity from Drew University.

(Source: Global Healing Email [Announcement](#), 1/15/19) ♠

MEMBER NEWS

South Texas Blood & Tissue Center (STBTC) has partnered with Macopharma and Calimex to interface Macopharma’s automated blood mixer, MacoMix HM20, with STBTC’s blood establishment computer system (BECS). “We are very excited to have accomplished this goal” said Elizabeth Waltman, chief operating officer at STBTC in a news release. “It was a challenging task, however, as a result of this wireless integration of the MacoMixer, phlebotomy data is delivered seamlessly into the BECS. Along with error reduction, now we are able to streamline production with real-time stats streaming directly from every collection site, fixed and mobile.”

(Source: Macopharma and South Texas Blood & Tissue Center Announcement, 1/22/19)

Ohio State Wexner Medical Center recently announced that **Versiti** will supply its blood and blood product needs. “We’re extremely proud to partner with an acclaimed healthcare institution such as The Ohio State University Wexner Medical Center,” said Chris Miskel, MBA, president and CEO of Versiti in a news [release](#). “As blood health innovators with expertise in hematology and transfusion medicine – as well as world renowned research – we’re dedicated to serving the needs of Wexner Medical Center and helping to ensure the best patient outcomes. Through the ongoing generosity of Ohio blood donors, we’re committed to serving as a beacon of hope for even more patients in need.” Andrew Thomas, MD, chief clinical officer at Ohio State



(continued on page 7)



MEMBER NEWS (continued from page 6)

Wexner Medical Center added, “As one of the top hospitals in the nation, the Midwest’s largest cancer hospital and the area’s only academic medical center, we treat the most complex patients and perform the area’s most complicated treatments and procedures requiring blood and blood products. This will help improve our patient care through innovations and efficiencies. We look forward to working with [Versiti] to support our highly specialized needs.”

(Source: Versiti and Ohio State Wexner Medical Center News [Release](#), 1/17/19)



Cascade Regional Blood Services (CRBS) and Key Biologics, LLC reached agreement for CRBS to supply researchers with blood products and materials to further their research and product manufacturing. “We are excited to partner with Key Biologics and expand upon our long history of supporting research activities,” said Christine Swinehart, CEO of CRBS in a news [release](#). We look forward to offering our donors new opportunities for saving lives and contributing to scientific advancements.” The collection of mononuclear cells by leukapheresis will be the focus of the partnership. “This

partnership immediately expands Key Biologics collection and supply footprint and gives us the ability to serve a much broader segment of the market,” said Joe Gentile, CEO of Key Biologics. “The Northwest is an important and growing area for vital medical research and CRBS has the state-of-the-art facilities, expertise, and an engaged donor base to support those efforts.”

(Source: Cascade Regional Blood Services and Key Biologics News [Release](#), 1/16/19)

National Institutes of Health Director Francis Collins, MD, PhD recently visited **San Diego Blood Bank** as part of the All of Us research initiative. It focuses on disease prevention and treatment through precision medicine and individualized care for patients with a goal of recruiting 1 million participants.

(Source: San Diego Blood Bank Announcement 1/11/19) 💧

Left to right: NIH Director Francis Collins, MD, PhD and San Diego Blood Bank CEO David Wellis, PhD.



INFECTIOUS DISEASE UPDATES

EBOLA

The Ebola outbreak in the Democratic Republic of Congo (DRC) is ongoing. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) have not classified the affected areas as having “widespread transmission of Ebola virus,” which would trigger donor interventions in the U.S. The U.S. Food and Drug Administration (FDA) [guidance](#) requires that “in the event that one or more countries is classified by CDC as having widespread transmission of Ebola virus, your donor history


(continued on page 8)

INFECTIOUS DISEASE UPDATES (continued from page 7)

questionnaire (DHQ), including your full-length and abbreviated DHQ, and accompanying materials, must incorporate elements to assess prospective donors for symptoms of recent or current illness with Ebola virus infection or disease, and travel to, or residence in, an area endemic for Ebola virus in accordance with 21 CFR 630.10(e)(2).”

As of January 22nd, there were 713 reports (664 confirmed and 49 probable) with 439 deaths.


Confirmed and probable Ebola virus disease cases by week of illness onset, data as of January 22nd (n=713)*



*Data in recent weeks are subject to delays in case confirmation and reporting, as well as ongoing data cleaning. Trends during this period should be interpreted cautiously.

(Source: [Ebola virus disease – Democratic Republic of the Congo, 1/24/19](#)) ♦

STOPLIGHT®: Status of America’s Blood Centers’ Blood Supply





ABC 2019 Meetings & Workshops				
Meeting/Workshop	Dates	Location	Hotel/Hotel Rate	Registration Dates & Fees
Annual Meeting	March 23-26	Washington, DC	Ritz-Carlton (Pentagon City), \$259/night	Register here by Mar. 1 \$760
Technical & Quality Workshop	April 30-May 2	Minneapolis, Minnesota	Embassy Suites, \$139/night	Mid-Feb. (Early Bird TD or QA or TD + QA) \$360/\$435; Feb. 23-Apr. 5 (TD or QA or TD + QA) \$420/\$495
ADRP Annual Conference	May 14-16	Indianapolis, Indiana	Hyatt Regency, \$179/night	Register here now Subscribers \$575/\$695 non-subscribers
Medical Directors Workshop	July 30 (precedes Summer Mtg)	Denver, Colorado	Grand Hyatt, \$239 CAD/night	Late April - July 5 MD Workshop \$435 MD+Summer \$760
Summer Meeting	July 31-August 1	Denver, Colorado	Grand Hyatt, \$239 CAD/night	Late April - July 5 Summer \$655 Summer+MD \$760
Notes: For the most up-to-date information on all events, members of ABC may check the calendar on ABC's Member Site. Non-members may attend all events; information will be updated on ABC's Public Site .				



CALENDAR

Note to subscribers: Submissions for a free listing in this calendar are welcome. Send information to Leslie Maundy by e-mail (lmaundy@americasblood.org) or by fax to (202) 899-2621. (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)

2019

March 6-7. **IPFA 4th Asia Workshop on Plasma Quality and Supply, Hanoi, Vietnam.** More details available [here](#).

March 23. **2019 International Blood Safety Forum, Washington, D.C.** More details available [here](#).

March 24-26. **2019 ABC Annual Meeting, Washington, D.C.** More details available [here](#).

(continued on page 10)

CALENDAR (continued from page 9)

April 23-24. **15th Annual FDA and the Changing Paradigm for HCT/P Regulation, Washington, D.C.** More details available [here](#).

April 30-May 2. **2019 ABC Technical & Quality Workshop, Minneapolis, Minn.** More details coming soon.

May 14-16. **ADRP Annual Conference, Indianapolis, Ind.** More details available [here](#).

May 22-23. **IPFA/PEI 26th International Workshop on “Surveillance and Screening of Blood-Borne Pathogens”, Krakow, Poland.** More details available [here](#).

July 30-Aug. 1. **2019 ABC Medical Directors Workshop & Summer Meeting, Denver, Colo.** More details coming soon.



CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC institutional members. There are charges for non-members: \$139 per placement for *ABC Newsletter* subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, contact Leslie Maundy at the ABC office. Phone: (202) 654-2917; fax: (202) 899-2621; e-mail: lmaundy@americasblood.org.

POSITIONS

Chief Medical Officer (America’s Blood Centers). Reporting to the Chief Executive Officer (CEO), the Chief Medical Officer (CMO) is responsible for implementing strategies and tactics, consistent with the best scientific and medical evidence and regulatory requirements, that support America’s Blood Centers’ (ABC) mission, maintain our values, and realize our vision. The CMO works as part of the ABC Senior Executive Team (SET) to communicate ABC’s issues to members, regulators, legislators, and external groups and mobilizes ABC members and professional staff to achieve the strategic goals of the organization. The CMO serves as a public advocate for ABC, maximizing the organization’s public presence as a national leader in shaping the future of blood banking, transfusion medicine, and cell therapies. Responsibilities: Represent independent non-profit community blood centers on scientific, medical, and technical matters as well as donor and patient safety concerns before federal agencies, industry and other business partners, allied domestic and international organizations, scientific societies, the media, and the public. Advise the CEO, ABC Board of Directors, and ABC member centers on medical, scientific, technical, safety, and policy issues germane to blood banking. Stay apprised of pertinent regulatory developments and develop effective strategies to achieve success on regulatory issues affecting ABC members. Education & Experience: Medical Degree required. U.S. medical license required with board certification in a medical specialty. Board certification in pathology, transfusion medicine, hematology, or infectious disease preferred. Ten or more years’ experience related to blood banking or transfusion medicine. Three or more years’ experience with healthcare and/or blood

banking issues at a national level via committee work, offices held, or other appropriate experience. Administrative experience in a leadership role preferred. Please click [here](#) to view the full job description. To apply, please submit a resume and cover letter to [Kate Fry](#).

Director, Fixed Site Operations. We Are Blood serves over 40 hospitals and medical facilities in a 10-county area. We are currently hiring a Director, Fixed Site Operations. Responsibilities: Subject matter expert for Donor Services: Develop and sustain complete familiarity with all industry guidelines, cGMP, technical skills, departmental SOPs, quality policies and procedures, human resources policies and procedures, mainframe donor database, document management software, operator manuals, training plans and other materials as appropriate. Administration of managerial functions: Direct, manage, and evaluate work activities of the Lamar Operations and Satellite Managers; ensure compliance with all applicable industry, federal and organizational guidelines, protocols, policies, and procedures. Employee development: Function as a mentor to fixed site and support staff; providing leadership, guidance, training and counsel; investigate and rectify employee performance and/or behavioral inadequacies with timely counseling; conduct fair, effective, unbiased and factual performance appraisals of department managers and ancillary staff. Project Management: Work with Donor Services Quality Assurance Manager to establish, implement and validate new processes, protocols, procedures, and technologies; draft and revise SOPs; record keeping and organizational

(continued on page 11)

POSITIONS (continued from page 10)

leadership. To view the full posting, click [here](#). EEO Employer: Minorities/Women/Veterans/Disabled

Director, Mobile Operations. We Are Blood serves over 40 hospitals and medical facilities in a 10-county area. We are currently hiring a Director, Mobile Operations. Responsibilities: Subject matter expert for Donor Services: Develop and sustain complete familiarity with all industry guidelines, cGMP, technical skills, departmental SOPs, quality policies and procedures, human resources policies and procedures, mainframe donor database, document management software, operator manuals, training plans and other materials as appropriate. Administration of managerial functions: Direct, manage, and evaluate work activities of the Business Integration Services (BIS) manager and mobile operations managers; ensure compliance with all applicable industry, federal and organizational guidelines, protocols, policies, and procedures. Employee development: Function as a mentor to mobile operations and BIS support staff; providing leadership, guidance, training and counsel; investigate and rectify employee performance and/or behavioral inadequacies with timely counseling; conduct fair, effective, unbiased and factual performance appraisals of department managers and ancillary staff; project management, record keeping, and organizational leadership. To view the full posting, click [here](#). Check us out at www.WeAreBlood.org to find out how you else you can be a part of our family. EEO Employer: Minorities/Women/Veterans/Disabled

Chief Information Officer. LifeShare Blood Center is currently seeking a Chief Information Officer. The Chief Information Officer (CIO) is responsible for directing the information technology (IT) and communication strategy, and data integrity of LifeShare. The CIO oversees and manages the Project Management Office. This scope includes all data centers, technical service centers, production scheduling functions, help desks, data communication networks, computer program development, and computer systems operations. The CIO provides overall management, definition, and strategic planning of all computer and communication activities within the organizations; and provides insight to the C-suite and Board of Trustees on Information Technology and systems. Bachelor's degree in Computer Science or Business with emphasis in information management systems is required. A graduate degree is preferable. Ten plus years' experience in successive leadership with knowledge of contracting, negotiating, organization development, accounting, strategic planning, and supervision. Five plus years in an FDA regulated environment is highly desirable; blood-banking experience is advantageous. This position will be in our Shreveport, LA location. Review complete job description and submit applications at www.lifeshare.org/careers.

Medical Technologist, Clinical Laboratory Scientist, or Medical Laboratory Scientist (MT/CLS/MLS; 2nd or 3rd Shift Available). The Community Blood Center/Community Tissue Services is located in Dayton, OH. We are looking for a **Medical Technologist, Clinical Laboratory Scientist, or Medical Laboratory Scientist** to join our team of blood/tissue bank laboratory professionals. Our microbiology department is growing! We are expecting a volume of 437,000 tests this year. This position will be on either 2nd or 3rd shift. We perform sterility testing on all tissue grafts, and leukoreduced apheresis units, culture other blood products as needed and provide environmental surveillance cultures. If you haven't thought about working at a blood center or tissue bank give us a call. We'd be glad to give you a tour and tell you more about how we operate. The job consists of performing clinical microbiology testing. BS Required. ASCP certified as a Medical Technologist (MT), Clinical Laboratory Scientist (CLS), or Medical Laboratory Scientist (MLS). We offer a highly competitive benefit package including medical, vision, dental, life and supplemental insurance options, 401(k) with employer contribution and match, tuition assistance and generous paid time off (PTO). *CBC/CTS is an Equal Opportunity Employer/Protected Veteran/Disability. Drug-Free Workplace.* Visit our website to apply www.cbccs.org.

Medical Director. Provide transfusion medicine (TM) clinical care at Heartland Blood Center (HBC) and its associated hospitals in the scope noted below, as well as effort in leadership of the Immunohematology Reference Laboratory (IRL) as Medical Director at HBC/Versiti. Key components of this position would comprise TM consultation and oversight of blood management at HBC and Versiti partner hospitals, as well as participation in educational initiatives and clinical/applied research within both Versiti blood centers and their affiliated health systems. Primary Responsibilities: Oversees blood donor center collections in the Chicago-land and various areas of Indiana. Provides medical direction, including compliance with local, state, and federal regulations and accreditation agencies, for blood center and transfusion services at Versiti affiliated hospitals in Illinois and Indiana. IRL Medical Director for HBC, providing oversight of IRL laboratory staff technical duties and working with Versiti and HBC laboratory management to provide education and skill advancement. Education and Licenses: M.D. or D.O. Degree. Board certified in pathology (AP/CP or CP only), internal medicine, or pediatrics (with subspecialty boards in hematology). Board certified/board eligible in Blood Banking/Transfusion Medicine (American Board of Pathology—ABP). Current or eligible for medical licenses in Illinois, Wisconsin, Indiana, Michigan and Ohio. Experience/Certifications: Demonstrated experience in both 1) pathology/laboratory medicine or hematology and 2) transfusion medicine. Ability to write lectures and

(continued on page 12)



POSITIONS (continued from page 11)

articles using original or innovative techniques or styles; excellent presentation skills with capacity to present to varied audiences. Click [here](#) to view the full job description and to apply.

Blood Center Nurse – LPN or RN (Lee Health, Fort Myers, FL; Full – Time (8:00 AM – 4:30 PM)). This RN will float to other campuses. There is one week per month of 24hr call. Responsible for drawing blood and platelets from volunteer blood donors. Duties include interacting with prospective donors, providing information about blood donation, screening donors by conducting a mini-physical and a medical history interview, drawing blood according to specific procedures, administering post-donation care, and assisting donors who may experience reactions during or following their donation. Must complete detailed documents and records pertaining to the donation. Performs therapeutic apheresis procedures to provide treatments. Performs donor registration and audit with the blood center computer. Other duties include preparing work areas and restocking supplies. Clerical duties include phone reception, operation of office equipment such as fax machines, copy machines, and printers, in addition to basic computer skills in the Blood Bank computer system. Requirements: Less than one year of work related experience working a hospital environment, blood donation center or dialysis. Experience in apheresis or dialysis procedures preferred. Registered nurse license or license practical nurse. To apply, please visit: <https://jobs.leehealth.org/bloodnurse>. *Drug/Tobacco - free workplace. EOE*

Lead Therapeutic Apheresis Nurse – RN (Lee Health, Fort Myers, FL; Full – Time (8:00 AM – 4:30 PM)). Lead Therapeutic Apheresis Nurse will lead our nursing team in providing therapeutic apheresis services to patients in all of our hospitals. This position will travel to all five of Lee Health's hospitals and help coordinate all patient treatments. This position qualifies for relocation assistance and exceptional benefits. Duties: Assists medical director and pathologists with coordinating and planning apheresis treatment procedures and photopheresis treatments. Investigates and resolves problems concerning therapeutic apheresis procedures. Provides training and conducts competency assessments for therapeutic apheresis nurses. Communicates and disseminates information and policy and procedure changes to staff. Monitors equipment performance, quality control, and quality assurance and implements corrective action as required. Continuously interacts and consults with the leadership of the Donor Center and Clinical Laboratory. Effectively communicates and demonstrates good customer service skills. Requirements: Associate's or bachelor's degree in nursing. One year of donor center experience preferred. Registered nurse license: currently licensed or eligible for RN licensure in the state of Florida. BLS (American Heart Association/Basic Life

Support). Member of the American Society for Apheresis (AFSA) desirable. To apply, please visit: <https://jobs.leehealth.org/apheresis.Drug/Tobacco> - free workplace. *EOE*

Medical Director. LifeShare Blood Center is currently seeking a Medical Director. The Medical Director provides oversight for LifeShare Blood Center, and LifeShare Cellular, Molecular, and Tissue Services and provides medical support and consultation to centers when requested concerning donors, donor reactions, physician or hospital requests, apheresis services or any related procedures. Additional responsibilities include investigating suspected transfusion transmitted diseases and submitting required reports, reviewing reports of transfusion reactions and taking appropriate action, reviews reports of post-donation illnesses and makes decisions concerning product disposition, reviews abnormal donor test results and all positive infectious disease test results and makes appropriate notifications. Medical Doctor with appropriate specialty, such as hematology or pathology required. Louisiana license must be in good standing. Experience or fellowship in blood banking helpful. Demonstrated excellence as a physician or medical practitioner, either in private practice or in association with a major hospital or medical teaching institution. Knowledge of all regulations, laws, statutes and standards (e.g. FDA, AABB, CLIA, FACT) pertaining to blood donation, transfusion transmitted disease testing, blood compatibility and transfusion, cellular therapies, molecular testing, blood components, and patient or donor reactions. This position will be in our Shreveport, LA location. Review complete job description and submit applications at www.lifeshare.org/careers.

Vice President of Blood Services (Bloodworks Northwest). The incumbent will: Serve as an active member of the leadership team, providing strategic and operational expertise to achieve Blood Services goals. Manage the operational activities of a large technical and support staff engaged in the collection of donated blood and its preparation, testing, labeling and distribution. Assure compliance with policies, programs, and directives set forth by regulatory agencies and the organization. Establish and execute meaningful continuous improvement, coordinate laboratory functions with Transfusion Services to achieve efficient and effective blood resource management within the region. Responsible for preparing, recommending and subsequently executing a departmental profit and loss budget, inclusive of all relevant financial and operational performance measures. Serve as the strategic analyst and integrator of evolving healthcare information and delivery trends. Lead the effort to provide blood donors with an optimal experience. Develop and maintain a highly engaged workforce. Hire and retain successful team. Serve on boards, committees

(continued on page 13)

POSITIONS (continued from page 12)

and task forces that promote Bloodworks within the community. Education & Experience: Medical, technical or nursing degree or equivalent combination of education and experience. Ten or more years of progressive leadership experience in blood collection and manufacturing (strongly preferred), or equivalent. Apply online [here](#).

Clinical Laboratory Scientist (Sign-on Bonus from \$1000 to \$5000). Donor Testing Laboratory at Hoxworth seeks a Clinical Laboratory Scientist for second shift position. This position performs routine and complex quality control testing of blood and blood components, as well as high-level evaluation, review and interpretation of test results. Candidates shall be able to perform with minimal supervision, be proficient in computerized data entry and retrieval functions, and communicate effectively with individuals within and outside the department. On-call rotation for weekends and holidays is required. The job requires a bachelor's degree and MT (ASCP), BB (ASCP) or CHT (ABHI); - OR- bachelor's degree and registry eligible; -OR- bachelor's degree and HEW certified medical technologist with two (2) years related experience; -OR- MLT with three (3) years related experience. Degree must be in biological science or related field. Visit the Hoxworth Blood Center website at www.hoxworth.org. ♦